Research output per year
Research output per year
Fingerprint
Dive into the research topics where Arne Van der Vreken is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
B7-H3 nanobody-based CAR T cells control multiple myeloma growth, while dual BCMA/B7-H3 CAR T cells overcome antigen escape
van der Vreken, A., Meeus, F., Tu, C., van den Broecke, L., Raimondi, V., Vescovini, R., Hanssens, H., Watté, F., Autaers, D., Aragon, M., Billiau, J., De Veirman, K., Vanderkerken, K., De Vlaeminck, Y., Franceschini, L., Lee, H., Neri, P., De Bruyne, E., Storti, P. & Giuliani, N. & 2 others, , 14 Nov 2025, In: Journal of Hematology & Oncology. 18, 17 p., 103.Research output: Contribution to journal › Article › peer-review
Open Access -
B7-H3 nanobody-based CAR T cells control Multiple Myeloma growth, while dual BCMA/B7-H3 CAR T cells overcome antigen escape
Van der Vreken, A., 25 Sept 2025.Research output: Unpublished contribution to conference › Poster
-
Immunopeptidomics identified antigens for mRNA-lipid nanoparticle vaccines with alpha-galactosylceramide in multiple myeloma therapy
Vreken, A. V. D., Thery, F., Tu, C., Mwangi, K., Meulewaeter, S., Beck, L. D., Janssens, E., Veirman, K. D., Vanderkerken, K., Bruyne, E. D., Franceschini, L., Impens, F., Verbeke, R., Lentacker, I., Menu, E. & Breckpot, K., Apr 2025, In: Journal for ImmunoTherapy of Cancer. 13, p. 1-14 14 p., e010673.Research output: Contribution to journal › Article › peer-review
Open Access2 Citations (Scopus) -
PYCR1 inhibition in bone marrow stromal cells enhances bortezomib sensitivity in multiple myeloma cells by altering their metabolism
Oudaert, I., van den Broecke, L., Aksoy, O., Lind, J., Vallet, S., Van der Vreken, A., Ates, G., Massie, A., Maes, K., De Veirman, K., De Bruyne, E., Vanderkerken, K., Podar, K. & Menu, E., 11 Sept 2025, In: Molecular Oncology. 17 p.Research output: Contribution to journal › Article › peer-review
Open Access -
Syntenin inhibition impairs stroma-tumor communication in multiple myeloma and improves bortezomib treatment efficiency
Tu, C., Leblanc, R., Van der Vreken, A., Koops, M., Audebert, S., Goullieux, L., Meeussen, S., De Veirman, K., De Bruyne, E., Vanderkerken, K., David, G., Cupedo, T., Zimmermann, P. & Menu, E., Aug 2025, In: HemaSphere. 9, 8, e70197.Research output: Contribution to journal › Article › peer-review
Open Access1 Citation (Scopus)
Datasets
-
Syntenin inhibition impairs stroma-tumor communication in Multiple Myeloma and improves Bortezomib treatment efficiency
Tu, C. (Creator), Leblanc, R. (Creator), Van der Vreken, A. (Creator), Koops, M. (Creator), Audebert, S. (Creator), Goullieux, L. (Creator), Meeusen, S. (Creator), De Veirman, K. (Creator), De Bruyne, E. (Creator), Vanderkerken, K. (Creator), David, G. (Creator), Cupedo, T. (Creator), Zimmermann, P. (Creator) & Menu, E. (Creator), Proteomics Identifications Database (PRIDE), 26 Jul 2025
https://www.ebi.ac.uk/pride/archive/projects/PXD064458
Dataset
-
PYCR1 inhibition in bone marrow stromal cells enhances bortezomib sensitivity in multiple myeloma cells by altering their metabolism
Menu, E. (Creator), Oudaert, I. (Creator), Vanderkerken, K. (Creator), De Veirman, K. (Creator), De Bruyne, E. (Creator), Van der Vreken, A. (Creator), Ates, G. (Creator), Massie, A. (Creator) & Maes, K. (Creator), DRYAD, 6 Nov 2025
Dataset
-
Exploring omics-identified antigens and mRNA-lipid nanoparticle vaccines with alpha-galactosylceramide for multiple myeloma therapy
Menu, E. (Creator), Van der Vreken, A. (Creator), Tu, C. (Creator), De Beck, L. (Creator), Vanderkerken, K. (Creator), Breckpot, K. (Creator), De Veirman, K. (Creator), De Bruyne, E. (Creator) & Franceschini, L. (Creator), Proteomics Identifications Database (PRIDE), 7 May 2025
https://www.ebi.ac.uk/pride/archive/projects/PXD060156
Dataset
-
Hypoxia promotes BCMA loss and a suppressive secretome thereby hindering CAR T cell therapy in multiple myeloma
Menu, E. (Creator), Van der Vreken, A. (Creator), Tu, C. (Creator), De Bruyne, E. (Creator), van den Broecke, L. (Creator), Meeus, F. (Creator), Brons, J. (Creator), De Veirman, K. (Creator), Vanderkerken, K. (Creator) & Breckpot, K. (Creator), Gene Expression Omnibus (GEO), 11 Sept 2025
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE307311
Dataset
Prizes
-
-
-
FWO travelgrant
Van der Vreken, A. (Recipient) & Menu, E. (Recipient), 7 Feb 2024
Prize: Other distinction
-
B7-H3 nanobody-based CAR T cells control Multiple Myeloma growth, while dual BCMA/B7-H3 CAR T cells overcome antigen escape
Van der Vreken, A. (Speaker)
25 Sept 2025Activity: Talk or presentation › Talk or presentation at a conference
-
Long research stay abroad: University of Parma (Italy)
Van der Vreken, A. (Organiser)
1 May 2024 → 30 Jun 2024Activity: Other › Research and Teaching at External Organisation
-
Unveiling B7-H3 as novel target for CAR T-cell therapy in Multiple Myeloma
Van der Vreken, A. (Speaker) & Menu, E. (Contributor)
2 Feb 2024Activity: Talk or presentation › Talk or presentation at a conference